Replimune/$REPL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Replimune

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Ticker

$REPL
Sector
Primary listing

Employees

479

Replimune Metrics

BasicAdvanced
$365M
-
-$3.60
0.67
-

What the Analysts think about Replimune

Analyst ratings (Buy, Hold, Sell) for Replimune stock.

Bulls say / Bears say

The FDA accepted Replimune’s Biologics License Application for RP1 plus nivolumab under Priority Review with a PDUFA date of July 22, 2025, supported by primary IGNYTE trial data demonstrating a 33.6% overall response rate and 27.6-month median duration of response in anti-PD-1 failed melanoma patients. (GLOBE NEWSWIRE)
As of June 30, 2025, Replimune held $403.3 million in cash, cash equivalents, and short-term investments, providing a runway into the fourth quarter of 2026 to fund clinical development and potential RP1 commercialization. (BioSpace)
The company advanced its RP2 program with plans to dose the first patient in a biliary tract cancer cohort in the second half of 2025 and ongoing Phase 2 trials in HCC under a collaboration with Roche, diversifying risk beyond RP1. (SEC Filing)
On July 22, 2025, the FDA issued a Complete Response Letter for RP1’s BLA, deeming the IGNYTE trial inadequate, which caused Replimune’s stock to plummet by 75% in a single day, underscoring significant regulatory risk. (Barron's)
The company identified material weaknesses in its IT general controls and is facing a class action lawsuit alleging federal securities law violations, raising concerns over governance and financial reporting integrity. (Panabee)
Replimune burned $192.3 million in cash from operations in fiscal year 2025, highlighting a high cash-burn rate that will necessitate additional funding absent revenue generation. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Replimune Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Replimune Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REPL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs